edoc

Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial

Kappos, Ludwig and Li, David and Calabresi, Peter A. and O'Connor, Paul and Bar-Or, Amit and Barkhof, Frederik and Yin, Ming and Leppert, David and Glanzman, Robert and Tinbergen, Jeroen and Hauser, Stephen L.. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, Vol. 378, no. 9805. pp. 1779-1787.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004708

Downloads: Statistics Overview

Abstract

B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:The Lancet
ISSN:0140-6736
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:06 Dec 2013 09:35
Deposited On:06 Dec 2013 09:35

Repository Staff Only: item control page